Reflection on Statistical Innovations in The Past 25 Years of Alzheimer’s Disease Research

Although the focus of this presentation is on clinical trials, statisticians have and will need to continue contributing to all facets of drug development, including methods to help identify better drug candidates, AI and machine learning applications, risk prediction models, new diagnostics, and fluid and digital biomarker development and validation for surrogacy. With recently approved drugs, optimized designs for clinical trials of combination treatments will be needed.